Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04838600Terminated

A PMCF Investigation on Chronic LU and DFU in Need of Debridement With ChloraSolv®

Role: lead

NCT05547191Not ApplicableTerminated

Evaluate Efficacy and Safety of ChloraSolv When Treating Pressure Ulcers in Need of Debridement

Role: lead

NCT03808181Not ApplicableCompleted

An Open, Single-arm, Multi Centre Pilot Investigation to Evaluate the Debriding Effect of ChloraSolv® on Chronic Wounds

Role: lead

All 3 trials loaded